Becton, Dickinson and Company (NYSE:BDX) Updates FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 12.620-12.720 for the period, compared to the consensus estimate of 12.560. The company issued revenue guidance of -.

Becton, Dickinson and Company Stock Up 0.1%

Shares of NYSE:BDX opened at $170.30 on Thursday. The firm has a market capitalization of $46.93 billion, a P/E ratio of 43.11, a P/E/G ratio of 12.12 and a beta of 0.19. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock has a 50 day moving average price of $153.20 and a 200-day moving average price of $162.62. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.53 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of recent research reports. Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Bank of America dropped their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Barclays raised their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. The Goldman Sachs Group dropped their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Finally, Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus price target of $182.20.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,189 shares of company stock worth $765,661. Corporate insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at $29,000. Johnson Financial Group Inc. bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $33,000. Kelleher Financial Advisors purchased a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth $37,000. Finally, Miller Capital Partners Inc. purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth $43,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.